Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D01QSG
|
|||
| Former ID |
DNCL001733
|
|||
| Drug Name |
VTP-27999
|
|||
| Synonyms |
VTP-27999; C26H41ClN4O5; 6076AC; CS-0311; HY-50768; W-5512; 142C510; Carbamic acid, N-[2-[(R)-(3-chlorophenyl)[(3R)-1-[[[(2S)-2-(methylamino)-3-[(3R)-tetrahydro-2H-pyran-3-yl]propyl]amino]carbonyl]-3-piperidinyl]methoxy]ethyl]-, methyl ester
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Indication | Hypertension [ICD-11: BA00-BA04; ICD-9: 401] | Phase 1 | [1] | |
| Company |
Vitae Pharmaceuticals
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C26H41ClN4O5
|
|||
| Canonical SMILES |
CNC(CC1CCCOC1)CNC(=O)N2CCCC(C2)C(C3=CC(=CC=C3)Cl)OCCNC(=O)OC
|
|||
| InChI |
1S/C26H41ClN4O5/c1-28-23(14-19-6-5-12-35-18-19)16-30-25(32)31-11-4-8-21(17-31)24(20-7-3-9-22(27)15-20)36-13-10-29-26(33)34-2/h3,7,9,15,19,21,23-24,28H,4-6,8,10-14,16-18H2,1-2H3,(H,29,33)(H,30,32)/t19-,21-,23+,24+/m1/s1
|
|||
| InChIKey |
NXWASIVXQMMPLM-ZXMXYHOLSA-N
|
|||
| CAS Number |
CAS 942142-51-0
|
|||
| PubChem Compound ID | ||||
| PubChem Substance ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Angiotensinogenase renin (REN) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Renin-angiotensin system | |||
| Pathwhiz Pathway | Angiotensin Metabolism | |||
| Reactome | Metabolism of Angiotensinogen to Angiotensins | |||
| WikiPathways | ACE Inhibitor Pathway | |||
| Metabolism of Angiotensinogen to Angiotensins | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01217736) Direct Renin Inhibition and the Kidney. U.S. National Institutes of Health. | |||
| REF 2 | New Developments in the Pharmacological Treatment of Hypertension: Dead-End or a Glimmer at the Horizon . Curr Hypertens Rep. 2015; 17(6): 42. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.